Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Discover key takeaways from Viking Therapeutics' Q1 2025 earnings call, including Phase 3 trial updates, financial performance, and obesity ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Phase 3 clinical trial data on VK2735 arrives later this year, and phase 2 data on a GLP-1 pill could come out as early as Q2. Seedhouse doesn't beat around the bush: "Our thesis is entirely ...

CompanyOverview\|NASDAQ:VKTX] Viking Therapeutics Inc. (NASDAQ: VKTX)reported earnings after the market closed on Apr. 23.

"Throughout the first quarter we continued to ramp up activities in support of the initiation of Phase 3 trials with the subcutaneous formulation of VK2735, which are on track to begin later this ...

Viking Therapeutics Inc (VKTX) reports significant progress in clinical trials and maintains a strong cash position despite ...

The candidate, VK2735, also is being developed in a subcutaneous (injection) format, and that version is set to enter phase 3 trials during the second quarter of this year. VK2735, like Lilly's ...